Bio-Path Holdings, a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, has appointed Dr. Ana Maria Tari, PhD, director, preclinical operations and research.

Tari was a faculty member at the University of Texas M. D. Anderson Cancer Center from 1994 through 2009, holding positions as assistant professor and associated professor in the department of experimental therapeutics. In 2009, Tari became an Associate Professor at the University of Florida Gainesville, which she continues to hold.